# Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

> **NCT00626561** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Cervical Cancer
- Uterine Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00626561
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to slow accrual.
- **Last updated:** 2014-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626561, "Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00626561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*